As such, the GSK3β mediated Keap1-independent regulation of Nrf2 activity may be a actionable therapeutic target for hindering post-AKI CKD transition and for improving the long-term outcome of AKI. The gene discussed is GSK3B; the disease is chronic kidney disease.